DDLS
MCID: DDF001
MIFTS: 45

Dedifferentiated Liposarcoma (DDLS)

Categories: Cancer diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Dedifferentiated Liposarcoma

MalaCards integrated aliases for Dedifferentiated Liposarcoma:

Name: Dedifferentiated Liposarcoma 11 58 14 16
Liposarcoma, Dedifferentiated 71
Liposarcoma Dedifferentiated 53
Ddls 58

Characteristics:


Prevelance:

1-9/1000000 (Europe) 58

Age Of Onset:

Adult 58

Classifications:



External Ids:

Disease Ontology 11 DOID:0080531
NCIt 49 C3704
ICD10 via Orphanet 32 C49.9
UMLS via Orphanet 72 C0205824
Orphanet 58 ORPHA99970
UMLS 71 C0205824

Summaries for Dedifferentiated Liposarcoma

Orphanet: 58 Dedifferentiated liposarcoma (DDLS) is a high-grade subtype of liposarcoma (LS; see this term) that progresses from well-differentiated liposarcoma (WDLS; see this term), and most often occurs in the retroperitoneum. It is defined as a region of nonlipogenic sarcoma associated with WDLS. .

MalaCards based summary: Dedifferentiated Liposarcoma, also known as liposarcoma, dedifferentiated, is related to liposarcoma and pleomorphic liposarcoma. An important gene associated with Dedifferentiated Liposarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways/superpathways are Cellular Senescence and Endometrial cancer. The drugs Doxorubicin and Anti-Bacterial Agents have been mentioned in the context of this disorder. Affiliated tissues include lymph node, bone and colon, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Disease Ontology: 11 A liposarcoma that is characterized as a high-grade tumor that occurs when a lower-grade tumor changes and creates new high-grade cells.

Related Diseases for Dedifferentiated Liposarcoma

Diseases related to Dedifferentiated Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 418)
# Related Disease Score Top Affiliating Genes
1 liposarcoma 32.1 TP53 RB1 PPARG MDM2 HMGA2 EWSR1
2 pleomorphic liposarcoma 32.0 TP53 SSX2 SS18 SERPINA3 MDM2 KIT
3 well-differentiated liposarcoma 31.5 TP53 SSX2 SS18 SERPINA3 MDM2 KIT
4 cutaneous fibrous histiocytoma 31.5 SERPINA3 S100B F13A1 DES CD34 ACTC1
5 fibrous histiocytoma 31.4 SERPINA3 S100B F13A1 EWSR1 DES CD34
6 lipomatosis, multiple 31.4 TP53 SERPINA3 MDM2 KIT HMGA2 EWSR1
7 osteogenic sarcoma 31.3 TP53 RB1 MIR199A1 MDM2 CDK4
8 fibrosarcoma 31.3 TP53 KIT EWSR1 DES ACTC1
9 malignant fibrous histiocytoma 31.2 TP53 SERPINA3 S100B MDM2 KIT F13A1
10 sarcoma 31.2 TP53 SSX2 SS18 SERPINA3 S100B RB1
11 retroperitoneal sarcoma 31.0 MDM2 KIT HMGA2 CDK4 CD34
12 leiomyosarcoma 31.0 TP53 SERPINA3 S100B RB1 MDM2 KIT
13 inflammatory myofibroblastic tumor 30.9 TP53 SSX2 SS18 MDM2 KIT EWSR1
14 mesenchymal cell neoplasm 30.9 TP53 SSX2 SS18 SERPINA3 MIR199A1 MDM2
15 spindle cell liposarcoma 30.9 MDM2 CDK4 CD34
16 sclerosing liposarcoma 30.9 MDM2 KIT CD34
17 retinoblastoma 30.9 TP53 RB1 PPARG MDM2 CDK4
18 colonic benign neoplasm 30.9 TP53 SERPINA3 PPARG MIR199A1
19 malignant peripheral nerve sheath tumor 30.8 TP53 S100B MDM2 KIT CDK4 CD34
20 desmoid tumor 30.8 TP53 MDM2 KIT DES CD34 ACTC1
21 rhabdomyosarcoma 30.8 TP53 SSX2 S100B RB1 MDM2 KIT
22 malignant inflammatory fibrous histiocytoma 30.8 SERPINA3 MDM2 CDK4 CD34
23 fasciitis 30.8 TP53 DES CD34 ACTC1
24 myxofibrosarcoma 30.8 TP53 SSX2 SS18 SERPINA3 MDM2 KIT
25 malignant mesenchymoma 30.8 SSX2 SERPINA3 MDM2 CD34
26 mixed liposarcoma 30.8 TP53 MDM2 KIT CDK4 CD34
27 sarcomatosis 30.8 KIT EWSR1
28 mediastinum liposarcoma 30.7 MDM2 CDK4
29 spindle cell sarcoma 30.7 TP53 SSX2 SS18 SERPINA3 S100B MDM2
30 inflammatory liposarcoma 30.7 MDM2 CDK4 CD34
31 myxoid liposarcoma 30.7 TP53 SSX2 SS18 MDM2 KIT HMGA2
32 bone sarcoma 30.6 TP53 SERPINA3 MIR199A1 MDM2 EWSR1 CDK4
33 infiltrating lipoma 30.6 MDM2 HMGA2 CDK4 CD34
34 retroperitoneal leiomyosarcoma 30.6 KIT CD34
35 extraosseous osteosarcoma 30.6 MDM2 KIT CDK4 CD34
36 uterus leiomyosarcoma 30.6 KIT HMGA2 DES ACTC1
37 connective tissue benign neoplasm 30.6 TP53 SERPINA3 MDM2 KIT EWSR1 CDK4
38 angiomyolipoma 30.6 TP53 KIT DES ACTC1
39 breast malignant phyllodes tumor 30.6 TP53 SERPINA3 KIT CD34
40 li-fraumeni syndrome 30.6 TP53 RB1 MDM2 CDK4
41 meningioma, familial 30.5 TP53 SERPINA3 S100B MDM2 KIT EWSR1
42 pseudosarcomatous fibromatosis 30.5 SS18 SERPINA3 KIT EWSR1 DES CD34
43 myoma 30.5 TP53 KIT HMGA2 CD34 ACTC1
44 melanoma, cutaneous malignant 1 30.5 TP53 RB1 MDM2 KIT CDK4
45 spindle cell lipoma 30.5 MDM2 HMGA2 DDIT3 CDK4 CD34
46 heart cancer 30.5 SS18 SERPINA3 MDM2 KIT CD34
47 vascular cancer 30.5 TP53 SERPINA3 KIT EWSR1 CD34
48 small cell cancer of the lung 30.4 TP53 RB1 KIT
49 neurilemmoma 30.4 SERPINA3 S100B KIT DES CD34 ACTC1
50 epithelioid sarcoma 30.4 SSX2 SS18 SERPINA3 EWSR1 CD34

Graphical network of the top 20 diseases related to Dedifferentiated Liposarcoma:



Diseases related to Dedifferentiated Liposarcoma

Symptoms & Phenotypes for Dedifferentiated Liposarcoma

GenomeRNAi Phenotypes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CD34 CDK4 DDIT3 DES F13A1 MDM2

MGI Mouse Phenotypes related to Dedifferentiated Liposarcoma:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 ACTC1 CD34 CDK4 DDIT3 DES EWSR1
2 neoplasm MP:0002006 10.21 CD34 CDK4 DDIT3 EWSR1 HMGA2 KIT
3 normal MP:0002873 10.19 ACTC1 CDK4 EWSR1 KIT MDM2 MIR193B
4 cellular MP:0005384 10.15 ACTC1 CD34 CDK4 DDIT3 DES EWSR1
5 endocrine/exocrine gland MP:0005379 10.14 CDK4 DDIT3 EWSR1 F13A1 HMGA2 KIT
6 muscle MP:0005369 10.11 ACTC1 CDK4 DES EWSR1 KIT MDM2
7 behavior/neurological MP:0005386 10.1 ACTC1 CDK4 DDIT3 DES EWSR1 F13A1
8 renal/urinary system MP:0005367 10.08 CDK4 EWSR1 HMGA2 KIT MDM2 PPARG
9 cardiovascular system MP:0005385 10.06 ACTC1 CDK4 DDIT3 DES F13A1 KIT
10 reproductive system MP:0005389 9.85 CDK4 EWSR1 F13A1 HMGA2 KIT MDM2
11 hematopoietic system MP:0005397 9.73 ACTC1 CD34 CDK4 DDIT3 EWSR1 F13A1
12 integument MP:0010771 9.44 CD34 CDK4 EWSR1 F13A1 HMGA2 KIT

Drugs & Therapeutics for Dedifferentiated Liposarcoma

Drugs for Dedifferentiated Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
2 Anti-Bacterial Agents Phase 2, Phase 3
3 Antibiotics, Antitubercular Phase 2, Phase 3
4 Liposomal doxorubicin Phase 2, Phase 3
5
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
6
Ifosfamide Approved Phase 2 3778-73-2 3690
7
Durvalumab Approved, Investigational Phase 2 1428935-60-7
8
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286
9
Nivolumab Approved Phase 2 946414-94-4
10
Ipilimumab Approved Phase 2 477202-00-9
11
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
12
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
13
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
14
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
15
Palifosfamide Investigational Phase 2 31645-39-3 100427
16 Immunoglobulins, Intravenous Phase 2
17 Immunoglobulin G Phase 2
18 Protein Kinase Inhibitors Phase 2
19 Immunoglobulins Phase 2
20 Antibodies, Monoclonal Phase 2
21 Antibodies Phase 2
22 Antineoplastic Agents, Immunological Phase 2
23 Immunologic Factors Phase 2
24 Immune Checkpoint Inhibitors Phase 2
25 Immunosuppressive Agents Phase 2
26 Alkylating Agents Phase 2
27 Antineoplastic Agents, Alkylating Phase 2
28 Hypoglycemic Agents Phase 2
29
Avelumab Approved, Investigational Phase 1 1537032-82-8
30 Poly I-C Phase 1

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma Recruiting NCT05218499 Phase 2, Phase 3 BI 907828;Doxorubicin
2 SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma Recruiting NCT04967521 Phase 3 Abemaciclib;Placebo
3 A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) Active, not recruiting NCT02606461 Phase 2, Phase 3 Selinexor;Placebo
4 A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients With Dedifferentiated Liposarcoma Active, not recruiting NCT04979442 Phase 3 RAIN-32;Trabectedin
5 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT02571829 Phase 2 ribociclib
6 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT03096912 Phase 2 Ribociclib
7 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Unknown status NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
8 Phase II Trial of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma Completed NCT01913652 Phase 2 Cabazitaxel
9 A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Completed NCT02247544 Phase 2 Trabectedin
10 A Phase II Multi-Arm Study to Test the Efficacy of Oleclumab and Durvalumab in Multiple Sarcoma Subtypes Recruiting NCT04668300 Phase 2
11 A Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated Dedifferentiated Liposarcoma Recruiting NCT04438824 Phase 2 INCMGA00012;Palbociclib
12 A Phase II Study, With a Safety lead-in, to Evaluate ATX-101, a Peptide Drug Targeting PCNA, in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma Recruiting NCT05116683 Phase 2 ATX-101
13 Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Active, not recruiting NCT03307616 Phase 2
14 Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma Active, not recruiting NCT02500797 Phase 2
15 Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) Active, not recruiting NCT03114527 Phase 2 Ribociclib;Everolimus
16 Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma Active, not recruiting NCT02846987 Phase 2 Abemaciclib
17 Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Active, not recruiting NCT03989596 Phase 2
18 A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial of TQB3616 Capsules Versus Placebo in the Treatment of Dedifferentiated Liposarcoma Not yet recruiting NCT05496569 Phase 2 TQB3616 capsule;TQB3616 placebo
19 A Phase 2 Multicenter, Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas Not yet recruiting NCT05580588 Phase 2 SPH4336
20 A Phase II Study on Trabectedin in Combination With PPARg Agonist Pioglitazone in Patients With Round Cell Myxoid Liposarcomas or Dedifferentiated G1 and G2 Liposarcomas With Stable Disease After a Monotherapy With Trabectedin. (TRABEPIO) Not yet recruiting NCT04794127 Phase 2 Trabectedin;Pioglitazone Oral Product
21 Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial Terminated NCT01876043 Phase 2 plitidepsin
22 A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma Withdrawn NCT00969917 Phase 2 IPI-504
23 A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients With Advanced Solid Tumors Recruiting NCT03604783 Phase 1 TP-1287
24 A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma Active, not recruiting NCT04242238 Phase 1 DCC-3014;Avelumab
25 A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma Active, not recruiting NCT04420975 Phase 1
26 Correlation of DDLS Grading to OCT, HRT, and HVF Completed NCT00430287

Search NIH Clinical Center for Dedifferentiated Liposarcoma

Genetic Tests for Dedifferentiated Liposarcoma

Anatomical Context for Dedifferentiated Liposarcoma

Organs/tissues related to Dedifferentiated Liposarcoma:

MalaCards : Lymph Node, Bone, Colon, Breast, Lung, Retina, Salivary Gland

Publications for Dedifferentiated Liposarcoma

Articles related to Dedifferentiated Liposarcoma:

(show top 50) (show all 969)
# Title Authors PMID Year
1
Well-differentiated and dedifferentiated liposarcomas. 53 62
19688222 2010
2
Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. 53 62
19946100 2009
3
SNP genotyping of a sclerosing rhabdomyosarcoma: reveals highly aneuploid profile and a specific MDM2/HMGA2 amplification. 53 62
19454362 2009
4
Other targetable sarcomas. 53 62
19664496 2009
5
Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. 53 62
18820664 2009
6
Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. 53 62
18836421 2009
7
Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. 53 62
18500263 2008
8
Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. 53 62
18204431 2008
9
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. 53 62
17638873 2007
10
alpha-fetoprotein expression in a dedifferentiated liposarcoma. 53 62
16489442 2006
11
[Extragastrointestinal stromal tumors: a report of 4 cases]. 53 62
16472759 2006
12
Alterations of the RB1 gene in dedifferentiated liposarcoma. 53 62
15933756 2005
13
MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. 53 62
16160477 2005
14
Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. 53 62
12640106 2003
15
Significance of loss of heterozygosity of the RB1 gene during tumour progression in well-differentiated liposarcomas. 53 62
12210086 2002
16
Fine needle aspiration cytology of a dedifferentiated liposarcoma: report of a case with histologic and immunohistochemical follow-up. 53 62
11480734 2001
17
Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component. 53 62
11484509 2001
18
Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature. 53 62
11518050 2001
19
Fibrohistiocytic differentiation in subcutaneous fatty tumors. Study of spindle cell, pleomorphic, myxoid, and atypical lipoma and dedifferentiated liposarcoma cases composed in part of CD34+ fibroblasts and FXIIIa+ histiocytes. 53 62
9331894 1997
20
Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. 53 62
9071997 1997
21
Extending depolarized DLS measurements to turbid samples. 62
35839555 2022
22
Assessment of optic disk by disk damage likelihood scale staging using slit-lamp biomicroscopy and optical coherence tomography in diagnosing primary open-angle glaucoma. 62
36453304 2022
23
Atypical spindle cell/pleomorphic lipomatous tumor with a sarcomatous component showing high mitotic activity and Ki-67 labeling index: report of a unique case mimicking dedifferentiated liposarcoma. 62
35779129 2022
24
Genomic alterations and clinical outcomes in patients with dedifferentiated liposarcoma. 62
36464833 2022
25
Dedifferentiated liposarcoma in the abdominal cavity: a case report. 62
36315383 2022
26
Resection of the mediastinal dedifferentiated liposarcoma with trachea compression via the Masaoka approach. 62
35739027 2022
27
Giant retroperitoneal dedifferentiated liposarcoma mimicking ovarian cancer: A case report. 62
36299399 2022
28
Chloroquine Combined With Rapamycin Arrests Tumor Growth in a Patient-derived Orthotopic Xenograft (PDOX) Mouse Model of Dedifferentiated Liposarcoma. 62
36309387 2022
29
MRI findings to differentiate musculoskeletal dedifferentiated liposarcoma from atypical lipomatous tumor. 62
36350422 2022
30
Landmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal Sarcoma. 62
36088426 2022
31
A Contemporary Clinicopathologic Analysis of Primary Sarcomas of the Perinephric Soft Tissue and Hilar Vessels Including a Subset Secondarily Involving the Kidney. 62
36437683 2022
32
Transcriptome analysis identifies TODL as a novel lncRNA associated with proliferation, differentiation, and tumorigenesis in liposarcoma through FOXM1. 62
36167276 2022
33
Is preoperative CT-guided biopsy a valuable tool in the diagnostic workup of patients with visceral and retroperitoneal sarcoma? 62
35985092 2022
34
Liposarcoma With Hibernoma-like Histology: A Clinicopathologic Study of 16 Cases. 62
35475774 2022
35
Histopathological Correlation of Chromosome 12 Polysomy by Fluorescence in Situ Hybridization in Adipocytic Neoplasms. 62
35261272 2022
36
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). 62
35980618 2022
37
A rare case of parapharyngeal dedifferentiated liposarcoma in a 12-year-old boy. 62
36300908 2022
38
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry. 62
36196483 2022
39
Paratesticular Dedifferentiated Liposarcoma with Epithelioid Features: A Diagnostic Pitfall. 62
36113458 2022
40
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. 62
36151848 2022
41
Dedifferentiated liposarcoma found in ovary: A rare case report. 62
36123846 2022
42
Dedifferentiated liposarcoma in the extremity and trunk wall: A multi-institutional study of 132 cases by the Japanese Musculoskeletal Oncology Group (JMOG). 62
36088237 2022
43
Primary dedifferentiated liposarcoma of the breast: A case report. 62
36093467 2022
44
Surgery of intraabdominal giant dedifferentiated liposarcoma of ascending colon mesentery: A rare case report. 62
35973321 2022
45
Hypopharyngeal dedifferentiated liposarcoma treated by endoscopic submucosal dissection. 62
36068123 2022
46
[STAT6 positive dedifferentiated liposarcoma: a clinicopathological analysis of two cases]. 62
35922170 2022
47
[The special case-Dedifferentiated liposarcoma of the spermatic cord]. 62
35960320 2022
48
Dedifferentiated liposarcoma of the gallbladder: A rare case report. 62
36041902 2022
49
Primary dedifferentiated liposarcoma mimicking malignant gastric stromal tumor. 62
35963700 2022
50
First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. 62
35561319 2022

Variations for Dedifferentiated Liposarcoma

Expression for Dedifferentiated Liposarcoma

Search GEO for disease gene expression data for Dedifferentiated Liposarcoma.

Pathways for Dedifferentiated Liposarcoma

Pathways related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.61 CDK4 HMGA2 MDM2 RB1 TP53
2
Show member pathways
12.58 TP53 RB1 MDM2 KIT CDK4
3 12.41 TP53 MDM2 KIT DDIT3 CDK4 ACTC1
4 12.4 TP53 RB1 MDM2 CDK4
5
Show member pathways
12.31 TP53 RB1 MDM2 KIT CDK4
6
Show member pathways
12.11 TP53 RB1 MDM2 CDK4
7
Show member pathways
12.1 TP53 RB1 MDM2 CDK4
8
Show member pathways
12.07 TP53 RB1 MDM2 CDK4
9 11.99 CDK4 MDM2 RB1 TP53
10
Show member pathways
11.95 TP53 RB1 MDM2 CDK4
11 11.78 TP53 RB1 CDK4
12 11.74 PPARG KIT DES CD34
13 11.7 TP53 PPARG MDM2
14
Show member pathways
11.67 RB1 PPARG HMGA2 CDK4
15 11.64 TP53 RB1 CDK4
16 11.6 CDK4 MDM2 RB1 TP53
17 11.54 TP53 RB1 CDK4
18 11.5 RB1 DDIT3 CDK4
19 11.34 TP53 MDM2 CDK4
20 11.31 RB1 PPARG MDM2 CDK4
21 11.06 TP53 RB1 MDM2 CDK4
22 10.95 TP53 RB1 MDM2
23 10.84 TP53 RB1 MDM2 CDK4
24 10.77 RB1 CDK4
25 10.49 TP53 RB1
26 10.44 TP53 RB1 MDM2 CDK4

GO Terms for Dedifferentiated Liposarcoma

Biological processes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10 TP53 PPARG KIT HMGA2 CD34 ACTC1
2 negative regulation of gene expression GO:0010629 9.76 TP53 RB1 PPARG MIR199A1 CD34
3 regulation of cell cycle GO:0051726 9.65 TP53 RB1 MDM2 DDIT3 CDK4
4 cellular response to actinomycin D GO:0072717 8.92 TP53 MDM2

Molecular functions related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 9.43 TP53 RB1 MDM2
2 RNA polymerase II-specific DNA-binding transcription factor binding GO:0061629 9.32 TP53 RB1 HMGA2 DDIT3 CD34

Sources for Dedifferentiated Liposarcoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....